Activity jointly provided by the American Epilepsy Society and AKH Inc., Advancing Knowledge in Healthcare
Release date: April 30, 2021 
Expiration date: April 30, 2024

Overview
This internet based enduring interactive module explores current advances in the diagnosis and treatment of new-onset and drug-resistant epilepsies. Experts will cover treatment of new onset epilepsy and address genetic testing and psychogenic non-epileptic seizures (PNES).

Treatment of New Onset Epilepsy (Moderator: Heather McKee, MD)

• Case: Treatment, Susan Axelrod, MBA
• Lecture: Treatment of First Seizure in Adults, Katherine Noe, MD, PhD
• Lecture: Genetic Testing When and What to Order, Scott Demarest, MD
• Lecture: The Role of the Neurologist in Initiating Treatment of PNES, Benjamin Tolchin, MD, MS
• Debate: Do We Have to Wait for DRE to Resect a Lesion? Guy M, McKhann, MD, FAANS and Allyson L. Alexander, MD, PhD

Target Audience
Advanced Practice Providers, Behavioral Health Providers, Clinicians, Fellows/Trainees, Nurses, Pharmacists, Scientists, and Technicians

Learning Objectives
Following participation in this activity, participants will be able to:

• Identify etiologies of epilepsy that will impact early treatment of epilepsy 

Resolution of Conflicts of Interest
It is the policy of the American Epilepsy Society and AKH to ensure balance, independence, objectivity and scientific rigor. All persons involved in the selection, development and presentation of content are required to disclose any real or apparent conflicts of interest. In accordance with the ACCME Standards of Integrity and Independence in Accredited Continuing Education, the AES implemented the mechanisms of prospective peer review of this CME activity, to identify and resolve any conflicts. Additionally, the content of this activity is based on the best available evidence.


Planning Committee, Faculty Reviewers’ Disclosures of Financial Relationships
In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, the AES requires that any person who is in a position to control content of a CME activity must disclose all relevant financial relationships that they have with an ineligible company. Unless otherwise indicated (*), none of the planners or faculty of this activity have any financial relationships to disclose. All relevant financial relationships with ineligible companies have been mitigated. The following individuals contributed to this activity’s content.

Planning Committee and Faculty
Kelly Knupp MD, MSCS – Consultant: Bicodex, Epygenix, Zogenix; Contract research: West Therapeutics
Heather McKee, MD
Susan Axelrod, MBA
Katherine Noe, MD, PhD
Scott Demarest, MD – Consultant: Marinus, Neurogene, Ovid
Benjamin Tolchin, MD, MS
Guy M, McKhann, MD, FAANS – Consultant: Koh Young
Allyson L. Alexander, MD, PhD

CME Reviewer
Sonal Bhatia, MD
Jonathan Kuo, MD
Kenneth Myers, MD
Fawad Khan, MD
Joel Oster, MD

AKH CE Planners and Reviewers
Dorothy Caputo, MA, BSN, RN (planner)
Bernadette Marie Makar, MSN, APRN, BC, NP-C (reviewer)
Dorothy Duffy, BS Pharmacy (reviewer)

American Epilepsy Society Staff Planners
Cristina Graham
Kandice Kidd, MA

Accreditation
The American Epilepsy Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

For more information regarding contact hours, please call American Epilepsy Society 312.883.3800 or education@aesnet.org.

Credit Designation
The American Epilepsy Society designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


I support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and the American Epilepsy Society. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nursing
Credit being awarded: 1.5 ANCC contact hours

Pharmacists
AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 1.5 contact hours.

If you have questions regarding accredited CE credit, please contact AKH at JGoldman@akhcme.com.

Commercial Support
No commercial support was received for this activity.

CME/CE Certificate
To receive credit for your participation in this activity, please complete the evaluation survey provided at the conclusion of the activity.

Unapproved Use Disclosure
The American Epilepsy Society and AKH requires accredited CME/CE authors to disclose to learners when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information. Information about pharmaceutical agents/devices that is outside of U.S. Food and Drug Administration approved labeling may be contained in this activity.

Disclaimer
This accredited CME/CE activity is for educational purposes only and does not constitute the opinion or endorsement of, or promotion by, the American Epilepsy Society or AKH Inc., Advancing Knowledge in Healthcare. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label, investigational and/or experimental uses.